Invitation to presentation of Xbrane Biopharma’s interim report January – Juni 2020 on August 21, 2020.

Corporate Information

English

News

Presentation

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on August 21, 2020, at 10.00 a.m. CET. Xbrane will publish the company’s interim report January – June 2020, on Friday August 21, 2020, at 8.00 a.m. CET.

Martin Åmark, CEO, and Susanna Helgesen, CFO, will present Xbrane and comment on the interim report January – June 2020, followed by a Q&A session. The presentation will be in English. To attend, please dial-in at one of the numbers below:

Standard international: +44 (0) 2071 928 338
UK (Local): +44 (0) 844 481 97 52
UK (Tollfree): 08 002 796 619
Sweden (Local): +46 (0) 850 692 180
Sweden (Toll Free): 020 012 51 60
US (LocaL): +1 646 741 31 67
US (Toll Freee): +1 877 870 91 35

Confirmation Code: 4598698

Web link:
https://edge.media-server.com/mmc/p/iacxcxxa

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.